LBIO (Longevity Biomedical) Debt-to-Equity: 0.00 (As of . 20)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

What is Longevity Biomedical Debt-to-Equity?

Longevity Biomedical LBIO Debt-to-Equity is 0.00 as of . 20.

Longevity Biomedical's Short-Term Debt & Capital Lease Obligation for the quarter that ended in . 20 was $0.00 Mil. Longevity Biomedical's Long-Term Debt & Capital Lease Obligation for the quarter that ended in . 20 was $0.00 Mil. Longevity Biomedical's Total Stockholders Equity for the quarter that ended in . 20 was $0.00 Mil.

A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.

The historical rank and industry rank for Longevity Biomedical's Debt-to-Equity or its related term are showing as below:

LBIO's Debt-to-Equity is not ranked *
in the Biotechnology industry.
Industry Median: 0.155
* Ranked among companies with meaningful Debt-to-Equity only.

Longevity Biomedical  (NAS:LBIO) Debt-to-Equity Explanation

In the calculation of Debt to Equity, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Stockholders Equity. In some calculations, Total Liabilities is used to for calculation.

Be Aware

Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.

Longevity Biomedical Debt-to-Equity Related Terms

Longevity Biomedical Debt-to-Equity Historical Data

* Premium members only.

The historical data trend for Longevity Biomedical's Debt-to-Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Longevity Biomedical Debt-to-Equity Chart

Longevity Biomedical Annual Data
Trend
Debt-to-Equity

Longevity Biomedical Semi-Annual Data
Debt-to-Equity

LBIO vs : Debt-to-Equity Comparison

For the Biotechnology subindustry, Longevity Biomedical's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Longevity Biomedical Debt-to-Equity vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Longevity Biomedical's Debt-to-Equity distribution charts can be found below:

* The bar in red indicates where Longevity Biomedical's Debt-to-Equity falls into.


Longevity Biomedical Debt-to-Equity Calculation

Debt to Equity measures the financial leverage a company has.

Longevity Biomedical's Debt to Equity Ratio for the fiscal year that ended in . 20 is calculated as

Debt to Equity=Total Debt / Total Stockholders Equity
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / Total Stockholders Equity
=( + ) / N/A
=N/A

Longevity Biomedical's Debt to Equity Ratio for the quarter that ended in . 20 is calculated as

Debt to Equity=Total Debt / Total Stockholders Equity
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / Total Stockholders Equity
=( + ) /
=N/A

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Debt-to-Equity →
What does a Debt-to-Equity of 0.00 mean?
Longevity Biomedical (LBIO) has a Debt-to-Equity of 0.00 as of . 20. Debt-to-Equity ratio represents the ratio of total debt to total company equity. View historical data on Longevity Biomedical and its competitors.
Is Longevity Biomedical's Debt-to-Equity too high?
Longevity Biomedical's current Debt-to-Equity is 0.00.
How does Longevity Biomedical's Debt-to-Equity compare to ?
Longevity Biomedical's Debt-to-Equity of 0.00 can be compared against companies in the Biotechnology industry. The industry median Debt-to-Equity is 0.16. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Debt-to-Equity for a Biotechnology company?
The median Debt-to-Equity among Biotechnology companies is 0.16, based on 964 companies in the industry. Companies in the top quartile (top 25%) have a Debt-to-Equity significantly above this median, while those in the bottom quartile fall well below. However, Debt-to-Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Debt-to-Equity mean?
A high Debt-to-Equity can signal that a stock is expensive relative to its fundamentals. Debt-to-Equity ratio represents the ratio of total debt to total company equity. View historical data on Longevity Biomedical and its competitors. For the Biotechnology industry, the median Debt-to-Equity is 0.16 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Longevity Biomedical's current Debt-to-Equity is 0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Longevity Biomedical stock overvalued right now?
Longevity Biomedical (LBIO) has a current Debt-to-Equity of 0.00. The current Debt-to-Equity is 0.00. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Debt-to-Equity calculated?
Debt-to-Equity is calculated from a company's financial statements. For Longevity Biomedical (LBIO), the current Debt-to-Equity is 0.00 as of . 20. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Longevity Biomedical Business Description

Comparable Companies
Address 12100 NE 195th street, Suite 150, Bothell, WA, USA, 98011
Longevity Biomedical Inc is a clinical-stage biomedical company. The company is focused on the advancement of new technologies across therapeutics, monitoring, and digital health that aim to restore tissue form and function to increase health span. Longevity is acquiring a differentiated therapeutic pipeline of late-stage clinical technologies across ophthalmology, cardiovascular disease, and soft tissue reconstruction and repair.